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Available online 16 May 2016To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for
blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had
received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment
satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and
Blepharospasm Disability Index (BSDI).
Subjects’ (n = 114) last treatment was onabotulinumtoxinA (n = 78), incobotulinumtoxinA (n = 35), or
abobotulinumtoxinA (n = 1). The most frequent injection interval was 12 weeks (46.5% subjects); 30.7% had
an interval N12weeks. Themain rationale for interval choicewas “tomaintain treatment efﬁcacy” (44.7%). How-
ever, 36.6% reported that treatment effects usually declinedwithin 8weeks; 69.6%within 10weeks. JRS and BSDI
scores indicated re-emergence of symptoms before re-injection, with 70.2% and 73.7% of subjects reporting
difﬁculties to drive and read, respectively. Overall, treatment satisfaction was high, but declined at the end of
the cycle. Many subjects (52.3%) would prefer an injection interval of b12 weeks; 30.6% of b10 weeks.
In conclusion, the survey results indicate that blepharospasm symptoms, such as difﬁculties to drive and read, re-
emerge at the end of a BoNT treatment cycle and that ﬂexible, individualized treatment intervals may improve
treatment satisfaction and outcomes.









Blepharospasm is a focal dystonia characterized by excessive invol-
untary closure of the eyelids caused by contraction of the orbicularis
oculi and other facial muscles [1]. Blepharospasm is a chronic, disabling
condition that affects patients’ quality of life, social interactions,
employment status, andmay lead to depression [2–5]. With prevalence, botulinum neurotoxin type A;
stonia; JRS, Self-administered
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. This is an open access article underestimates ranging from 16 per million (in Japan) to 133 per million (in
Southern Italy), primary blepharospasm is one of the most common
forms of adult-onset dystonia [6]. It predominantly occurs in patients
in their ﬁfties and sixties, and affects women more than men [6,7]. It
is estimated that at least 50,000 individuals in the USA are affected by
blepharospasm, corresponding to a prevalence of approximately 50
per million, with a female preponderance of 1.8:1 [8].
The recommended treatment option for blepharospasm, based on
US and European treatment guidelines as well as expert consensus, is
repeated intramuscular injections of botulinum neurotoxin (BoNT)
[9–11]. In the USA and Europe, three BoNT type A (BoNT/A) formula-
tions (abobotulinumtoxinA, Dysport®, Ipsen Biopharm Ltd., UK;
incobotulinumtoxinA, Xeomin®, Merz Pharmaceuticals GmbH,
Germany; onabotulinumtoxinA, Botox®, Allergan, Inc., USA) are
currently available commercially. At present, all three formulations are
licensed for the treatment of blepharospasm in Europe [12–14], while
only incobotulinumtoxinA and onabotulinumtoxinA are licensed for
the treatment of blepharospasm in the USA [15,16]. These formulations
are derived from the Hall strain of Clostridium botulinum; inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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neurotoxin-associated complexing proteins [17].
The efﬁcacy and safety of BoNT/A formulations for the treatment of
blepharospasm have been demonstrated in a number of controlled
clinical trials [18–24]. However, treatment effects are temporary and
patients require repeat injections. Current US and European prescribing
information for approved BoNT/A formulations recommend minimum
injection intervals of 12 weeks for the treatment of blepharospasm,
mainly due to concerns that shorter intervals might promote the devel-
opment of neutralizing antibodies and adverse events, with eyelid
ptosis and dry eyes being described as themost common adverse effects
of BoNT/A treatment for blepharospasm [13–16,25]. To date, only one
prospective clinical trial has been conducted in blepharospasm allowing
BoNT treatment intervals shorter than 12 weeks [19,26]. This study
included a randomized, placebo-controlled main period with one
incobotulinumtoxinA treatment followed by an open-label extension
periodwith up toﬁve incobotulinumtoxinA treatments at ﬂexible inter-
vals ≥6weeks, with a total treatment duration of up to 68weeks. In this
study, injection intervals b12 weeks were not associated with a higher
incidence of adverse events than intervals ≥12 weeks [27] and no pa-
tients developed neutralizing antibodies based on the sensitive mouse
hemidiaphragm assay [26]. Importantly, the study also revealed that
treatment intervals b12 weeks were clinically indicated in a consider-
able proportion of patients with blepharospasm, based on the clinical
need for re-injection as established by the investigator and conﬁrmed
by a Jankovic Rating Scale (JRS) severity subscore ≥2 [26]. Hence,
many patients with blepharospasm experienced recurrence of symp-
toms before the end of the current standard-of-care 12-week interval,
which may reduce quality of life.
We conducted a cross-sectional, structured survey in the USA in
subjects who received BoNT/A injections for blepharospasm. We
assessed BoNT/A treatment history, treatment intervals, physicians’
rationale for intervals, time course of patient-reported therapeutic ef-
fects, treatment satisfaction, patient-preferred treatment intervals,
Blepharospasm Disability Index (BSDI), and self-administered JRS
scores.
2. Material and methods
2.1. Ethics and regulatory requirements
The study protocol, informed consent, and other appropriate study-
related documents were reviewed and approved by an independent
ethics committee/institutional review board. The study was conducted
in accordance with the ethical principles that have their origin in the
Declaration of Helsinki, and are consistent with the International Con-
ference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use Good Clinical Practice guidelines
and applicable regulatory requirements. Written informed consent
was obtained from each subject prior to enrollment (i.e. prior to com-
pleting the survey). The trial was registered with ClinicalTrials.gov.
(NCT01686061).
2.2. Subjects
Subjects whowere eligible for participation included 18- to 80-year-
oldmen andwomenwith blepharospasmwho had completed ≥2 treat-
ment cycles with abobotulinumtoxinA, incobotulinumtoxinA, or
onabotulinumtoxinA. The survey focused on BoNT/A treatment only
and subjects were excluded if they had received rimabotulinumtoxinB
during any of the previous two treatment cycles.
Subjects were recruited at ﬁve clinical sites in the USA. All subjects
attending study sites to receive BoNT/A treatment for blepharospasm
were invited to enroll. Interviews took place immediately prior to sub-
jects’ next scheduled treatment, i.e. just before a re-injection. However,
the survey was a non-interventional study and no treatments wereadministered as part of the study. Survey data were collected via inter-
views conducted by study staff other than treating physicians; the same
member of staff conducted all interviews at each site, whenever
possible.
2.3. Patient survey
Demographics, baseline disease characteristics, medical history, pre-
vious BoNT/A treatment history and reasons for the chosen treatment
interval were retrieved from subjects’ medical records. The reasons for
the chosen treatment interval could be selected from a pre-deﬁned list
in the case report form (included as supplementary material), but
study staff had the option to specify other reasons if applicable. The
study then collected the following information about subjects’ perspec-
tives of BoNT/A treatment.
2.3.1. Botulinum toxin treatment – historical and current cycle
Subjects were asked to recall their BoNT/A treatment history (usual
treatment interval, reasons for the interval, and usual time to onset,
peak, and decline in effect) and experiences over the current injection
cycle (time to onset, peak, and decline in effect). Subjects were asked
when they would have preferred to have their next injection, if given
the choice.
2.3.2. Treatment satisfaction
Subjects rated their current satisfaction with BoNT/A treatment
using a numerical rating scale ranging from 1 to 10, where 1 was de-
ﬁned as not at all satisﬁed and 10 as very satisﬁed. Subjects were also
asked to recall their satisfaction at the peak effect of BoNT/A treatment
during their current cycle. Subjects with a rating of 1–3 were classiﬁed
as not at all satisﬁed, those with a rating of 4–7 as somewhat satisﬁed,
and those with a rating of 8–10 as very satisﬁed.
2.3.3. Blepharospasm disability index
Subjects completed the BSDI, a validated scale assessing functional
impairment in activities of daily living [21,28]. Items were rated on a
5-point scale from 0 (no impairment) to 4 (no longer possible due to
blepharospasm), or rated as non-applicable. Subjects were also asked
to recall their level of impairment at the peak of BoNT/A treatment
effect.
2.3.4. Jankovic rating scale
The JRS is a validated physician rating scale that includes a severity
item and a frequency item that are both scored from 0 (best) to 4
(worst) [18,28]. In this survey, we have used the JRS as a self-
administered instrument that was completed by subjects under the
guidance of clinic staff to rate blepharospasm symptoms (current and
at the peak of BoNT/A treatment effect).
2.4. Statistical methodology
Descriptive statistics were used to summarize all data. Continu-
ous variables were summarized by number, mean and standard devi-
ation (SD), and median value and range. Categorical variables were
summarized as counts and percentages. Percentages were based on
non-missing values. Statistical analysis was performed using the
SAS® software package (SAS Institute Inc., Cary, NC).
3. Results
The survey took place between September 2012 and April 2013.
Overall, 124 subjects participated in the survey and 91.9% (114/124)
were included in the ﬁnal analysis. The other 8.1% of subjects (10/124)
were excluded as they had not met the inclusion criterion for age.
Table 1




Female gender, n (%) 80 (70.2)
Mean (SD) age, years 66.1 (8.8)
Median (range) duration of blepharospasm, months 120 (12–900)
Type of blepharospasm,a n (%)
Mixed (clonic/tonic) 68 (59.7)
Primarily tonic 22 (19.3)
Primarily clonic 24 (21.1)
Comorbid chronic diseases requiring medical management,b n (%)
Any condition N= 95 (83.3)
Hypertension 47 (49.5)c
High cholesterol 41 (43.2)c
Thyroid problem 28 (29.5)c
Diabetes 21 (22.1)c
Depression/suicide 15 (15.8)c
Cancer (malignancy) 7 (7.4)c
Asthma 6 (6.3)c
Congenital heart disease 6 (6.3)c
Median (range) duration of BoNT/A treatment, months 96 (6–312)d
Last BoNT/A formulation given, n (%); mean (SD) dose
OnabotulinumtoxinA 78 (68.4); 71.8 (30.1) units
IncobotulinumtoxinA 35 (30.7); 76.4 (26.4) units
AbobotulinumtoxinA 1 (0.9); 100.0 (−) units
BoNT/A = botulinum neurotoxin type A; SD = standard deviation.
a Clonic blepharospasm is characterized by alternating contraction and relaxation of the
orbicularis oculiwhile tonic blepharospasm is characterized by sustained contraction.
b Subjects may have had more than one condition. Conditions occurring in N5% of sub-
jects are listed.
c Percentages are based on the number of subjects with comorbid conditions (n=95).
d Data available for 113 subjects.
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Subjects were aged 28–80 years (mean 66.1 [SD 8.8] years) with a
median duration of blepharospasm of 120 months. Most subjects
(70.2%, 80/114) were female. The majority of subjects (83.3%, 95/114)
had other chronic diseases requiring medical management (Table 1).
Subjects had received BoNT/A injections for blepharospasm for a
median of 96months. Table 1 also summarizes the BoNT/A formulations
and doses that subjects had received as their last treatment.
3.2. Time to onset, peak, and waning of BoNT/A treatment effect
Ninety-three percent of subjects (106/114) recalled usually
experiencing onset of treatment effect within 1 week of an injectionFig. 1. Time to subject-reported decline in botulinum neurotoxin type A treatment effect (n=
general, when do you usually feel a considerable decline in the effect of the botulinum toxin?”.
subjects within 4 weeks. †2 subjects reported effects usually decline 18 weeks after treatmentfor their previous treatments, with the remainder experiencing onset
within 2 weeks; 90.2% (101/112) recalled reaching the maximum or
peak effect in the ﬁrst 4 weeks after an injection. Although themajority
of subjects (69.6%, 78/112) reported that treatment effects declined
within 10 weeks of an injection and 36.6% (41/112) usually felt effects
declining within 8 weeks, waning of effect could also be reported as
late as 20 weeks post-injection (Fig. 1).
A very similar pattern was seen when subjects were asked about
their current treatment cycle speciﬁcally. In summary, 92.9% of subjects
(105/113) felt the onset of effect within 2weeks of treatment and 81.4%
(92/113) reported experiencing the peak effect within 4 weeks. Treat-
ment effects began to wear off within 10 weeks of the injection for
69.6% of subjects (78/112) and within 8 weeks for 35.7% (40/112).
One subject reported that no treatment effect had been present during
the current cycle.3.3. Current BoNT/A treatment intervals
Information from subjects’ medical records showed injections were
most frequently received at 12-week intervals (46.5%, 53/114). Nearly
one-third of subjects (30.7%, 35/114) had repeat injections at intervals
N12 weeks, including 3 subjects with intervals of 24 weeks. For the
remaining 22.8% of subjects (26/114), the treatment interval was
b12 weeks (Fig. 2). Overall, the mean (SD) treatment interval based
on the patient survey was 12.5 (3.3) weeks (median 12 weeks; range
3–24 weeks,).
From the subjects’ medical records, the reasons physicians had
chosen a subject’s treatment interval were “maintain efﬁcacy” (44.7%,
51/114), “standard procedure” (37.7%, 43/114), “insurance approval
guidelines” (15.8%, 18/114), “scheduling” (0.9%, 1/114), and “subject
does not need injection sooner” (0.9%, 1/114). These data were in good
agreement with the reason subjects recalled having been told by their
physicians: “maintain efﬁcacy” (59.6%, 62/104), “standard procedure”
(20.2%, 21/104), “insurance approval guidelines” (17.3%, 18/104),
“scheduling” (1.0%, 1/104), “when the patient needs it” (1.0%, 1/104),
and “frequent eye closure and spasms” (1.0%, 1/104). Ten subjects stated
they had not been given a reason for their treatment interval. Only one
reason was recorded for each subject.3.4. Treatment satisfaction
At the time of the interview, 56.1% of subjects (64/114) were at least
somewhat satisﬁed with BoNT/A treatment for blepharospasm, while112). Subjects were asked: “Over the course of all of your botulinum toxin treatments, in
⁎1 subject reported effects usually decline within 1 week, 2 subjects within 2 weeks, and 4
and 1 subject reported a decline 20 weeks after treatment.
Fig. 2.Botulinumneurotoxin typeA treatment intervals (frommedical records) (n=114). Intervalswithwhich the subject normally receives botulinum toxin injections, based onmedical
records. ⁎1 subject received intervals of 3 weeks. †3 subjects received intervals of 24 weeks.
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the peak of BoNT/A treatment effects (Table 2).3.5. Preferred injection intervals
When asked how often they would prefer to receive BoNT/A treat-
ment, the most frequent interval was 12 weeks (24.3%, 27/111)
(Fig. 3). However, most subjects (52.3%, 58/111) would prefer intervals
b12 weeks, including 30.6% of subjects (34/111) who would prefer in-
tervals b10 weeks. Nearly a quarter of subjects (23.4%, 26/111) would
prefer intervals N12 weeks.3.6. Blepharospasm disability index
At the time of the interview, 60.5% (69/114) to 73.7% (84/114) of
subjects reported impairmentwhen performing activities of daily living,
or an inability to perform these activities at all. At the peak of therapy
effect of the current cycle, 28.9% (33/114) to 38.6% (44/114) of subjects
recalled impairment or inability to perform activities of daily living
(Fig. 4).3.7. Jankovic rating scale
Based on self-assessments, the mean (SD) JRS severity and frequen-
cy scores at the time of the interview were 3.55 (1.07) and 3.43 (0.99),
respectively, indicating severe symptoms. At the time of peak effect of
the current cycle, the mean (SD) JRS severity and frequency scores
were 2.18 (0.93) and 2.20 (1.03), respectively (Fig. 5).Table 2




At the peak of
treatment effecta
(n= 113)
Very satisﬁed (NRS 8–10), n (%) 30 (26.3) 100 (88.5)
Somewhat satisﬁed (NRS 4–7), n (%) 34 (29.8) 10 (8.8)
Not at all satisﬁed (NRS 1–3), n (%) 50 (43.9) 3 (2.7)
Mean (SD) satisfaction score 6.2 (2.9) 8.8 (1.7)
Subjects were asked “How satisﬁed are you at themoment with the current effect of your
medication?” and “Compared to your current satisfaction with the effect of your medica-
tion, how satisﬁed were you when you felt the strongest effect of the medication?”.
NRS = numerical rating scale; SD = standard deviation.
a Based on subject recollection at the time of the interview, i.e. just prior to re-injection.4. Discussion
Blepharospasm is often a disabling condition that signiﬁcantly re-
duces patients’ quality of life [2–5]. Treatment with BoNT/A injections
temporarily reduces the symptoms of blepharospasm, is well tolerated,
andmay improve quality of life [18–24]. This structured surveywas car-
ried out to assess real-world treatment history, treatment intervals, pa-
tient satisfaction with treatment, time course of BoNT/A treatment
effects, preferred injection intervals, disability, and disease severity of
subjects who had received ≥2 complete cycles of BoNT/A treatment
for blepharospasm. The ﬁnal analysis included 114 subjects who, on av-
erage, had had a diagnosis of blepharospasm formore than 10 years and
had been treatedwith BoNT/A for most of that time. Most subjects were
women, reﬂecting the higher prevalence of blepharospasm in females.
The subjects included had a mean age of 66.1 years and, as expected
in a population of that age, the majority (83.3%) had other chronic
diseases requiring medical treatment.
Approximately two-thirds of the subjects received
onabotulinumtoxinA injections, and one-third received
incobotulinumtoxinA. The mean doses of onabotulinumtoxinA
(71.8 U) and incobotulinumtoxinA (76.4 U) administered at the
last treatment were similar for both formulations and in accordance
with the products’ labeling information [13–16]. One subject had re-
ceived abobotulinumtoxinA, a formulation that is not currently li-
censed for the treatment of blepharospasm in the USA. The most
frequent treatment interval was 12 weeks (46.5% of subjects) as
recommended by current product labeling, with nearly a third of
subjects (30.7%) receiving treatment at intervals N12 weeks. Less
than a quarter of subjects (22.8%) received treatment at intervals
shorter than recommended by current product labeling.
When asked about the time course of treatment effects, the vast
majority of subjects stated that they usually felt the onset of treatment
effect in the ﬁrst week and reached the peak of therapy effect within
the ﬁrst 4 weeks after treatment. However, there was noticeably more
variability between subjects in the time to waning of treatment effect.
Most subjects felt a considerable decline in BoNT/A treatment effects
within 8 to 10 weeks after injection. Given that 77.2% of subjects
received treatment at intervals of ≥12 weeks, these data suggest that
most subjects usually received re-injections after BoNT/A treatment
effects have begun to wane and therefore may have experienced recur-
rent blepharospasm symptoms toward the end of each injection cycle.
This was reﬂected in the BSDI and JRS assessments, showing that, at
the time of the interview,many subjects experienced functional impair-
ment due to recurrence of blepharospasm symptoms compared with
the peak of therapy effect. As a result, satisfaction with BoNT/A
Fig. 3. Subject preference for botulinum neurotoxin type A treatment intervals (n= 111). Subjects were asked: “If given the choice, when would you have preferred to have your next
injection?”. ⁎2 subjects preferred intervals of 1 week, 1 subject intervals of 2 weeks, 1 subject intervals of 4 weeks, and 4 subjects intervals of 6 weeks. †1 subject preferred intervals of
24 weeks.
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clined at the time of the interviews, which were conducted just before
a re-injection. It is important to note that the retrospective BSDI and
JRS assessments both indicated that even at the time of peak effect,
subjects still considered themselves to have signiﬁcant symptoms.
Our survey revealed that approximately half of all subjects (52.3%)
would prefer to receive BoNT/A treatment at intervals b12 weeks,
with nearly a third of all subjects (30.6%) preferring intervals
b10weeks. However, it needs to be borne inmind that almost a quarter
of subjects (23.4%) preferred injections at N12-week intervals showing
how patient preferences varied over a wide range of treatment inter-
vals. These data are similar to patient preferences found in surveys of
patients who received onabotulinumtoxinA or abobotulinumtoxinA
treatment for dystonia [29], and of patients who received any of the
three BoNT/A preparations for spasticity [30]. Both studies concluded
that patient satisfaction with BoNT/A declined toward the end of the
injection cycle and that many patients would like to be treated more
frequently than the intervals they received.
The 12-week standard-of-care BoNT/A treatment interval for
blepharospasm (and other indications) that is recommended in theFig. 4. Subject-reportedBlepharospasmDisability Index (n=114). Subjects rated items on a 5-p
them as non-applicable. Data shown are the percentage of subjects with a score of ≥1 (slight icurrent product labeling of BoNT/A formulations is partly based on a ret-
rospective study,where shorter injection intervalswere associatedwith
secondary non-response to BoNT/A in subjects with cervical dystonia
(CD) [31]. However, the study included only eight non-responders
and only three of those had serological evidence for neutralizing
antibodies against BoNT/A. In addition, the subjects in this study had
been treated with the original botulinum toxin formulation (Allergan
lot 79–11), which has since been shown to be more immunogenic
than later formulations of onabotulinumtoxinA [32]. Hence, the
relevance of these early ﬁndings for modern BoNT/A formulations is
unclear.
More recently, the efﬁcacy and safety of individualized treatment
regimens have been evaluated in two prospective clinical trials investi-
gating repeated incobotulinumtoxinA treatments for patients with
blepharospasm [19,26] and patients with CD [33,34]. Both studies in-
cluded a randomized, placebo-controlled main period during which
subjects could receive one treatment with incobotulinumtoxinA or pla-
cebo, followed by an open-label extension period in the blepharospasm
study or a randomized double-blind period in the CD study. Overall,
subjects could receive up to six incobotulinumtoxinA injections atoint scale from0 (no impairment) to 4 (no longer possible due to blepharospasm), or rated
mpairment or worse) for each item.
Fig. 5. Subject-reportedmean JRS severity and frequency scores (n=114). JRS frequency and severity scores range from 0 (best) to 4 (worst). Error bars represent the standard deviation.
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assessed by a physician using a validated clinical rating scale (JRS or To-
ronto Western Spasmodic Torticollis Rating Scale). A detailed post-hoc
analysis showed that in the blepharospasm study, 44.9% of treatments
were administered at injection intervals b12 weeks and 26.5% of injec-
tions were administered at intervals b10 weeks, which are very similar
to the intervals preferred by subjects in this survey. Importantly, there
were no differences in the overall incidence of adverse events or in
the incidence of the most frequent adverse events (dry eyes, ptosis,
and dry mouth), regardless of the incobotulinumtoxinA treatment in-
terval [27]. Similar results were seen in the CD survey and clinical trial
[27,29].
In this survey, the most important reason for the choice of BoNT/A
treatment interval was “to maintain treatment efﬁcacy”. This was in
contrast to the BSDI and JRS assessments, which suggested that efﬁcacy
was not optimally maintained toward the end of the treatment cycle for
many subjects. The analysis by Evidente et al. conﬁrmed that many pa-
tients who receive BoNT/A injections for blepharospasm have a clinical
need for re-injection b12 weeks after the previous treatment, based on
JRS assessments carried out by trained physicians [27]. It is important to
consider that the survey recorded only one reason for the choice of
treatment interval for each patient. This is potentially an important lim-
itation of this study since in clinical practice, physicians’ decisions are
based on a number of factors, including insurance approval guidelines.
However, insurance guidelines may not be recorded in medical records
as part of the rationale for choosing the treatment interval and may not
be communicated to patients. Hence, the surveymay underestimate the
inﬂuence of insurance approval guidelines on the choice of treatment
intervals in real-world practice.
Although the patient survey provides useful insight into the real-
world use and treatment satisfaction with BoNT/A, there are some
methodological limitations that need to be considered to contextual-
ize the ﬁndings. Only one reason for the chosen treatment interval
was recorded. Subjects’ responses were based on recollection of
their treatment experiences in general and their last treatment
cycle in particular. The JRS assessments were self-administered
under the guidance of clinic staff rather than conducted by trained
investigators. In addition, the small sample size may limit the gener-
alization of results to all patients with blepharospasm and does not
allow examination of potential predictors either of treatment satis-
faction or the time course of treatment effects, and potential correla-
tions between these variables. Further studies allowing such
analyses may be able to identify subsets of patients with blepharo-
spasm who are most likely to beneﬁt from shorter treatment
intervals.5. Conclusions
To our knowledge, this survey is the most comprehensive study
investigating patients’ preferences and treatment satisfaction with
BoNT/A treatment for blepharospasm to date. The survey revealed
that, overall, patient satisfaction with BoNT/A treatment regimens for
blepharospasm was very high. However, toward the end of the
treatment cycle, functional impairments and disability due to blepharo-
spasm, e.g. difﬁculties with everyday activities such as driving and
reading, worsened and patient satisfaction declined. More than half of
the patients surveyed expressed a desire to receive injections more fre-
quently than the current standard-of-care 12-week interval, suggesting
that more ﬂexible, individualized treatment intervals may improve
treatment satisfaction and outcomes for patients with blepharospasm.
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